Skip to content
Last run passedcali
UTC--:--:--

← startups

Alethio Therapeutics

alethiotherapeutics.com ↗ · Abingdon-on-Thames, United Kingdom · €80.46 million

via eu-startups.com · Nov 7
92/100Series Aqualified

A biotech company developing targeted monoclonal antibody therapies (e.g., ATX-011) for myeloproliferative neoplasms such as essential thrombocythaemia.

bottleneck › Scaling pre‑clinical and clinical manufacturing pipelines for biologics while integrating complex discovery data.

contact

✉ hello@alethiotx.com generalsource

☎ +441865538329source

linkedin ↗contact page ↗

pitch

We can build a Next.js dashboard that lets your scientists query experimental results with semantic vector search, cutting data‑retrieval time from days to seconds. This will free up your R&D team to focus on assay design and patient outcomes rather than hunting through spreadsheets.

email draft › hello@alethiotx.com

intent: build with them (no hiring signal or clear bottleneck, so propose a partnership)

Alethio Therapeutics: a thought on Scaling pre‑clinical and clinical manufacturing pipelines fo

Hi Adam,

Congrats on the new funding (https://www.eu-startups.com/2026/11/oxford-spin-out-alethio-therapeutics-raises-e80-46-million-series-a-to-advance-targeted-blood-cancer-therapies/).

I came across Alethio Therapeutics: A biotech company developing targeted monoclonal antibody therapies (e.g.
I'd like to build something with you.
One place we could start: scaling pre‑clinical and clinical manufacturing pipelines for biologics while integrating complex discovery data.

Open to a quick call to see if there is a fit?

If this isn't relevant, just reply "no" and I won't follow up.
address published on this page ↗
Open in mail

site built with

  • WordPress

signals

qualification

  • fit10000%
  • reach10000%
  • evidence8500%

timeline

  1. Nov 7 found · Stage: Series A · Raised: €80.46 million · HQ: Abingdon-on-Thames, United Kingdom · +18 moresource
  2. Nov 6 funding · Fundingsource

similar companies

score › fit 25/25 · identity 12/15 · people 20/20 · connections 15/20 · contact 20/20

missing › tech stack

people

  • Adam Mead · Co‑founder
    “Alethio was founded in 2021 as a spin‑out from the University of Oxford by Professors Adam Mead and Beth Psaila”
  • Beth Psaila · Co‑founder
    “Alethio was founded in 2021 as a spin‑out from the University of Oxford by Professors Adam Mead and Beth Psaila”
  • Rohit Batta · Chief Executive Officer in
    “Dr. Rohit Batta , Chief Executive Officer of Alethio Therapeutics”

connections

  • Adam Mead founded Alethio Therapeutics
    “Alethio was founded in 2021 as a spin‑out from the University of Oxford by Professors Adam Mead and Beth Psaila”
  • Beth Psaila cofounded Alethio Therapeutics
    “Alethio was founded in 2021 as a spin‑out from the University of Oxford by Professors Adam Mead and Beth Psaila”
  • Rohit Batta works at Alethio Therapeutics
    “Dr. Rohit Batta , Chief Executive Officer of Alethio Therapeutics”
  • Graziano Seghezzi invested in Alethio Therapeutics
    “The round was co‑led by new investors Sofinnova Partners and RA Capital, alongside founding investor Oxford Science Enterprises”
  • Maxwell DeNies invested in Alethio Therapeutics
    “The round was co‑led by new investors Sofinnova Partners and RA Capital, alongside founding investor Oxford Science Enterprises”
  • Sally Dewhurst backed by Alethio Therapeutics
    “Sally Dewhurst , Principal at Oxford Science Enterprises”

Trackbacks

Company

People

  • Adam Mead · Co‑founder verified · first seen Nov 7
    “Alethio was founded in 2021 as a spin‑out from the University of Oxford by Professors Adam Mead and Beth Psaila”
  • Beth Psaila · Co‑founder verified · first seen Nov 7
    “Alethio was founded in 2021 as a spin‑out from the University of Oxford by Professors Adam Mead and Beth Psaila”
  • Graziano Seghezzi · Managing Partner, Sofinnova Partners verified · first seen Nov 7
    “Graziano Seghezzi, Managing Partner at Sofinnova Partners, and Maxwell DeNies of RA Capital have joined Alethio’s Board of Directors”
  • Maxwell DeNies · Partner, RA Capital verified · first seen Nov 7
    “Maxwell DeNies of RA Capital have joined Alethio’s Board of Directors”
  • Rohit Batta · Chief Executive Officer verified · first seen Nov 7
    “Dr. Rohit Batta , Chief Executive Officer of Alethio Therapeutics”
  • Rohit Batta · linkedin matched · first seen Nov 7
    “Dr. Rohit Batta , Chief Executive Officer of Alethio Therapeutics”
  • Sally Dewhurst · Principal, Oxford Science Enterprises verified · first seen Nov 7
    “Sally Dewhurst , Principal at Oxford Science Enterprises”

Connections

  • Adam Mead founded Alethio Therapeutics verified · first seen Nov 7
    “Alethio was founded in 2021 as a spin‑out from the University of Oxford by Professors Adam Mead and Beth Psaila”
  • Beth Psaila cofounded Alethio Therapeutics verified · first seen Nov 7
    “Alethio was founded in 2021 as a spin‑out from the University of Oxford by Professors Adam Mead and Beth Psaila”
  • Graziano Seghezzi invested in Alethio Therapeutics verified · first seen Nov 7
    “The round was co‑led by new investors Sofinnova Partners and RA Capital, alongside founding investor Oxford Science Enterprises”
  • Maxwell DeNies invested in Alethio Therapeutics verified · first seen Nov 7
    “The round was co‑led by new investors Sofinnova Partners and RA Capital, alongside founding investor Oxford Science Enterprises”
  • Rohit Batta works at Alethio Therapeutics verified · first seen Nov 7
    “Dr. Rohit Batta , Chief Executive Officer of Alethio Therapeutics”
  • Sally Dewhurst backed by Alethio Therapeutics verified · first seen Nov 7
    “Sally Dewhurst , Principal at Oxford Science Enterprises”

Contact